SG Americas Securities LLC reduced its stake in shares of Mesa Laboratories, Inc. (NASDAQ:MLAB – Get Rating) by 55.2% in the third quarter, HoldingsChannel.com reports. The firm owned 4,740 shares of the medical instruments supplier’s stock after selling 5,846 shares during the period. SG Americas Securities LLC’s holdings in Mesa Laboratories were worth $668,000 as of its most recent SEC filing.
Several other large investors have also bought and sold shares of the stock. State of New Jersey Common Pension Fund D boosted its stake in Mesa Laboratories by 30.0% in the 3rd quarter. State of New Jersey Common Pension Fund D now owns 13,929 shares of the medical instruments supplier’s stock worth $1,962,000 after purchasing an additional 3,216 shares during the period. Raymond James & Associates grew its holdings in Mesa Laboratories by 3.8% in the 3rd quarter. Raymond James & Associates now owns 46,438 shares of the medical instruments supplier’s stock worth $6,540,000 after acquiring an additional 1,719 shares during the last quarter. Louisiana State Employees Retirement System bought a new stake in shares of Mesa Laboratories in the 3rd quarter worth approximately $338,000. Cambridge Investment Research Advisors Inc. boosted its stake in shares of Mesa Laboratories by 5.8% during the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 5,224 shares of the medical instruments supplier’s stock valued at $736,000 after purchasing an additional 285 shares in the last quarter. Finally, Mackenzie Financial Corp raised its position in shares of Mesa Laboratories by 20.3% in the 3rd quarter. Mackenzie Financial Corp now owns 1,437 shares of the medical instruments supplier’s stock worth $202,000 after acquiring an additional 242 shares in the last quarter. 93.00% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
MLAB has been the subject of a number of analyst reports. Evercore ISI raised their target price on shares of Mesa Laboratories to $166.00 in a research note on Tuesday, November 15th. StockNews.com downgraded shares of Mesa Laboratories from a “hold” rating to a “sell” rating in a research report on Saturday.
Insider Buying and Selling
Mesa Laboratories Price Performance
NASDAQ:MLAB opened at $196.88 on Friday. Mesa Laboratories, Inc. has a 52 week low of $114.21 and a 52 week high of $302.80. The company has a quick ratio of 2.13, a current ratio of 2.80 and a debt-to-equity ratio of 0.53. The stock has a market cap of $1.05 billion, a PE ratio of -259.05 and a beta of 0.68. The business’s 50-day simple moving average is $175.46 and its two-hundred day simple moving average is $170.57.
Mesa Laboratories (NASDAQ:MLAB – Get Rating) last released its earnings results on Thursday, November 3rd. The medical instruments supplier reported $2.07 earnings per share for the quarter, beating the consensus estimate of $0.83 by $1.24. The firm had revenue of $58.75 million for the quarter, compared to the consensus estimate of $53.24 million. Mesa Laboratories had a positive return on equity of 6.71% and a negative net margin of 1.78%. As a group, analysts forecast that Mesa Laboratories, Inc. will post 6.52 EPS for the current fiscal year.
Mesa Laboratories Dividend Announcement
The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 15th. Investors of record on Tuesday, February 28th will be paid a $0.16 dividend. This represents a $0.64 dividend on an annualized basis and a yield of 0.33%. The ex-dividend date is Monday, February 27th. Mesa Laboratories’s dividend payout ratio (DPR) is -84.21%.
Mesa Laboratories Company Profile
Mesa Laboratories, Inc develops, manufactures, and sells life sciences tools and quality control products and services in the United States, Europe, the Asia Pacific, and internationally. The company's Sterilization and Disinfection Control segment manufactures and sells biological, cleaning, and chemical indicators that are used to assess the effectiveness of sterilization and disinfection processes in the hospital, dental, medical device, and pharmaceutical industries.
- Get a free copy of the StockNews.com research report on Mesa Laboratories (MLAB)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving ’23 Growth
Receive News & Ratings for Mesa Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesa Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.